title: Efficiency of liposomes surface-modified with soybean-derived sterylglucoside as a liver targeting carrier in HepG2 cells.
abstract: We investigated the interaction of liposomes surface-modified with soybean-derived sterylglucoside (SG) (SG-liposomes) with HepG2 cells in the point of involvement of asialoglycoprotein receptor (ASGP-R) mediated endocytosis and examined the efficiency of SG-liposomes as drug carriers using 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI) as a maker of liposome, carboxylated polystyrene microspheres (Fluoresbrite) as a model drug not taken up in cells and doxorubicin (DXR). SG-liposomes were composed of dipalmitoylphosphatidylcholine (DPPC), cholesterol (Ch) and SG (DPPC/Ch/SG=6:3:1, molar ratio) and DiI, Fluoresbrite and DXR were entrapped in SG-liposomes, respectively. Each SG-liposome was incubated with HepG2 cells at 4 or 37 degrees C, and co-incubated with asialofetuin (AF) as a competitor of ASGP-R. The association of DiI, Fluoresbrite or DXR entrapped in SG-liposomes with HepG2 cells at 37 degrees C was significantly higher than that in liposomes containing no SG. That of DiI and Fluoresbrite was reduced significantly by the incubation with AF, but that of DXR was not affected. These findings suggest that Fluoresbrite behaves like the lipid component of SG-liposomes, but DXR in SG-liposomes does not behave similar to the lipid component of SG-liposomes, thus, its drug behavior released from liposomes may be due to its physicochemical properties. SG-liposomes are potentially useful drug carriers to the liver, because the glucose residue may work as a kind of ligand for ASGP-R.
authors.affiliation: Department of Pharmaceutics, Hoshi University, Ebara 2-4-41, Shinagawa-ku, 142-8501, Tokyo, Japan. yoshie@hoshi.ac.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Maitani
authors.forename: K
authors.initials: K
authors.lastname: Kawano
authors.forename: K
authors.initials: K
authors.lastname: Yamada
authors.forename: T
authors.initials: T
authors.lastname: Nagai
authors.forename: K
authors.initials: K
authors.lastname: Takayama
mesh_terms: D037263:Asialoglycoprotein Receptor; D001212:Asialoglycoproteins / Q000494:pharmacology; D002782:Cholestenes / Q000008:administration & dosage*; D004317:Doxorubicin / Q000008:administration & dosage; D004337:Drug Carriers; D004705:Endocytosis; D060748:Fetuins; D006801:Humans; D008081:Liposomes; D008099:Liver / Q000378:metabolism*; D011956:Receptors, Cell Surface / Q000502:physiology*; D012710:Serum Albumin, Bovine / Q000493:pharmacokinetics; D013025:Glycine max; D014407:Tumor Cells, Cultured; D000509:alpha-Fetoproteins / Q000494:pharmacology
chemical_list: D037263:Asialoglycoprotein Receptor; D001212:Asialoglycoproteins; D002782:Cholestenes; D004337:Drug Carriers; D060748:Fetuins; D008081:Liposomes; D011956:Receptors, Cell Surface; D000509:alpha-Fetoproteins; C017029:asialofetuin; C096056:soy derived sterylglucoside mixture; D012710:Serum Albumin, Bovine; D004317:Doxorubicin